Other Events ·
Braveheart Bio, Inc. filed its second amended and restated certificate of incorporation with the Delaware Secretary of…
BRVEBraveheart Bio, Inc.
Braveheart Bio, Inc. filed its second amended and restated certificate of incorporation with the Delaware Secretary of State on August 7, 2026, in connection with the completion of its initial public offering. The charter amendments authorize 500,000,000 shares of common stock, eliminate references to previously existing preferred stock series, and authorize 10,000,000 shares of undesignated preferred stock issuable at the Board's discretion. Additionally, the filing eliminates shareholder ability to take action by written consent or call special meetings. The company also adopted second amended and restated bylaws establishing formal meeting procedures and advance notice requirements for stockholder proposals. Braveheart Bio, Inc. operates in the biotechnology industry, focusing on drug discovery and development.